Speaker illustration

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)

Member of:

European Society of Cardiology

MD, PhD, Cardiologist, Clinical pharmacologist. Trained at Université de Lorraine, Université of Lyon, France and Medical Research Council (Oxford, UK). Currently, Emeritus Professor of Therapeutics at Université de Lorraine, France. As a trialist, he contributed to building the evidence supporting modern HF therapy, notably with beta-blockers, RAASi and MRAs. As a clinical scientist his work focuses on fibrosis and biomarkers. He has served as Chairman of the French Society of Hypertension, of the ESC Working Group on Pharmacology and Drug Therapy. He is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop with meetings in Paris, Washington DC, in Asia and the Middle East. Professor Zannad published more than 750 peer-reviewed papers. He received the 2014 European Society of Hypertension Paul Milliez Award and the 2017 Lifetime Achievement Award from the ESC-HFA and served as an Eugene Braunwald Scholar in 2019 at Harvard Medical School.

Ask the Trialists from Hot Line 8

Event: ESC Congress 2023

Topic: European Society of Cardiology

Session type: Ask the Trialists

Thumbnail

HOT LINE 5

Event: ESC Congress 2023

Topic: European Society of Cardiology

Session type: Hot Line

Thumbnail

Going beyond foundational therapy in HFrEF: what is the role of sGC stimulators?

Event: ESC Congress 2023

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session type: Satellite Symposium

Thumbnail

Meet the Gold Medallist – Bertram Pitt

Event: ESC Congress 2023

Topic: Other

Session type: Special Session

Thumbnail

Diabetic cardiomyopathy in heart failure: a new target for therapy

Event: Heart Failure 2023

Topic: e-Cardiology/Digital Health

Session type: Case-Based Session

Thumbnail

The practicalities of drug treatment in heart failure

Event: ESC Congress 2022

Topic: Chronic Heart Failure

Session type: Cardiology Toolbox

Thumbnail

Beta3 adrenergic agonists in the clinic: the end of the beginning

Event: ESC Congress 2022

Topic: Pharmacology and Pharmacotherapy

Session type: Special Session

Thumbnail

What's next for your patients following a worsening HF event?

Event: ESC Congress 2021 - The Digital Experience

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session type: Satellite Symposium

Thumbnail

Empagliflozin across the spectrum of ejection fraction in HF ‒ aggregate findings from the EMPEROR programme

Event: ESC Congress 2021 - The Digital Experience

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Neuromodulation for the management of patients with HFrEF: the present and the future

Event: ESC Congress 2021 - The Digital Experience

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb